CD4+ memory T cells retain surface expression of CD31 independently of thymic function in patients with lymphoproliferative disorders following autologous hematopoietic stem-cell transplantation

2017 ◽  
Vol 106 (1) ◽  
pp. 108-115 ◽  
Author(s):  
Egor V. Batorov ◽  
Marina A. Tikhonova ◽  
Irina V. Kryuchkova ◽  
Vera V. Sergeevicheva ◽  
Svetlana A. Sizikova ◽  
...  
Keyword(s):  
T Cells ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Memory T Cells ◽  
Surface Expression ◽  
Lymphoproliferative Disorders ◽  
Hematopoietic Stem ◽  
Thymic Function

scholarly journals Timing of CMV-specific effector memory T cells predicts viral replication and survival after allogeneic hematopoietic stem cell transplantation

2014 ◽  
Vol 27 (12) ◽  
pp. 1253-1262 ◽  
Author(s):  
Ildefonso Espigado ◽  
Fátima de la Cruz-Vicente ◽  
Omar J. BenMarzouk-Hidalgo ◽  
Irene Gracia-Ahufinger ◽  
Jose R. Garcia-Lozano ◽  
...  
Keyword(s):  
T Cells ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Memory T Cells ◽  
Effector Memory ◽  
Hematopoietic Stem ◽  
Effector Memory T Cells ◽  
Specific Effector

scholarly journals CNS relapse of B-lymphoblastic lymphoma after allogeneic hematopoietic stem cell transplantation: therapy with donor CD19-specific CAR-T cells

2021 ◽  
Vol 20 (2) ◽  
pp. 143-147
Author(s):  
O. O. Molostova ◽  
L. N. Shelikhova ◽  
D. E. Pershin ◽  
A. M. Popov ◽  
M. E. Dubrovina ◽  
...  
Keyword(s):  
T Cells ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Lymphoblastic Lymphoma ◽  
Hematopoietic Stem ◽  
Car T Cells ◽  
Car T ◽  
B Lymphoblastic Lymphoma

Presently, there is no consensus on the best treatment for relapsed B-cell acute lymphoblastic leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation (allo-HSCT), particularly in patients with extramedullary lesions. There are certain anti-tumor drugs that can be used in case of relapse after allo-HSCT, however, prospective randomized studies directly comparing different chemotherapy and immunotherapy approaches are generally lacking. Retrospective studies exploring therapy for relapsed disease are difficult to compare due to the inhomogeneity of patient populations and the diversity of treatment approaches. In such situations, the treatment choice is influenced by the characteristics of the tumor population, particularly, its immunophenotype, available drugs, and the experience of a healthcare facility and physicians. This clinical case report describes the process of treating a patient with B-lymphoblastic lymphoma and shows the possibility of using donor CD19-specific CAR-T cells as a treatment for isolated CNS relapse after allo-HSCT. The patient's parents gave their consent to the use of their child's data, including photographs, for research purposes and in publications.

Sign in / Sign up

Export Citation Format

Share Document